Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

RPH-104

Aliases
Arcerix, goflikicept, RPH-104 80 mg

8 clinical trials

9 indications

Indication
ST Segment Elevation Myocardial Infarction
Indication
Recurrent Pericarditis
Indication
Schnitzler syndrome
Indication
Urticarial Vasculitis With Monoclonal Immunoglobulin M Component
Indication
Schnitzler
Indication
Familial Mediterranean Fever
Indication
Adult-Onset Still's Disease
Indication
Adult-onset Still's disease
Indication
pericarditis
Clinical trial
International, Double Blind, Randomized, Placebo-controlled Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction
Status: Completed, Estimated PCD: 2021-11-03
Clinical trial
International, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of RPH-104 Treatment in Patients With Recurrent Pericarditis
Status: Not yet recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study of the Efficacy and Safety of RPH-104 in Adult Subjects With Schnitzler Syndrome
Status: Not yet recruiting, Estimated PCD: 2023-08-01
Clinical trial
International, Multicenter, Double Blind, Placebo-controlled, Randomized Clinical Study of Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of Colchicine
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
An International Multicenter Open-label Clinical Study of the Safety and Efficacy of RPH-104 for Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of Colchicine
Status: Recruiting, Estimated PCD: 2026-08-01
Clinical trial
International, Multi-Center, Double-blind, Randomized, Placebo-Controlled, Efficacy and Safety Clinical Study of RPH-104 in Adult Onset Still's Disease (AOSD)
Status: Withdrawn, Estimated PCD: 2025-08-01
Clinical trial
A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of RPH-104 Treatment in Patients With Idiopathic Recurrent Pericarditis
Status: Completed, Estimated PCD: 2022-01-24
Clinical trial
An Open-Label Clinical Study of the Safety and Efficacy of RPH-104 in Preventing Recurrences in Patients With Idiopathic Recurrent Pericarditis
Status: Active (not recruiting), Estimated PCD: 2026-01-01